The latest PR gives me new hope for Virulizin.
IL-17E is assoiated with Virulizin, I am a non-scientist so won't try to discuss the relationship.
"TORONTO, ONTARIO, Feb. 24, 2010 (Marketwire) -- Lorus Therapeutics Inc. (TSX:LOR)("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced a publication demonstrating the antitumor activity of a novel cytokine interleukin 17E (IL-17E). The article entitled "IL-17E, a pro-inflammatory cytokine, has antitumor efficacy against several tumor types in vivo" was published in the peer-reviewed journal, Cancer Immunology Immunotherapy and is currently available online on the Journal's website.
In this article, Lorus' scientists demonstrated the antitumor effects of IL-17E alone and in combination with a number of approved anticancer agents in preclinical models. The studies showed that IL-17E alone had potent antitumor activity in a number of solid tumors, including melanoma, breast, colon, pancreatic, and non-small cell lung cancers. In combination studies, IL-17E was compatible with a wide variety of approved anticancer drugs, including Avastin, Tarceva, Taxol, Cisplatin, Dacarbazine, Irinotecan, and Gemzar. Furthermore, the combination of IL-17E with each of these anticancer agents showed greater anticancer efficacy than either agent alone without additional toxicity."
Norman
The article also provided data on the mechanism of anticancer activity for IL-17E, showing that IL-17E activates the immune system, specifically acting on eosinophils and B cells. IL-17E stimulated the production of eosinophils and increased the infiltration of eosinophils into tumors in association with antitumor response. The studies also showed that B cells were necessary for IL-17E antitumor efficacy.
Norman
News 
Market Data 
Discover 
